Company
Nflection
NFlection is a clinical-stage biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei.
Also known as NFlection Therapeutics
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
Record updated 28 September 2026
About
We are a clinical-stage biotechnology company focused on the discovery and development of targeted therapies for skin disorders driven by aberrant activation of the RAS pathway. We are initially focused on the treatment of cutaneous neurofibromas in neurofibromatosis type 1, disfiguring congenital birthmarks (including keratinocytic epidermal nevi and nevus sebaceous), and the prevention of immunosuppressant-mediated squamous cell carcinoma.
Funding snapshot
- Total raised
- $44MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series A, $20M2020-06-09
Funding rounds
- Round, 2023
- $4M2023-07-07, SEC form D sold, 2 investors
- Round, 2022
- $20M2022-06-07, SEC form D sold, 2 investors
- Series A
- $20M2020-06-09, Company stated
- Round, 2016
- $20M2016-12-30, SEC form D sold, 2 investors
Products
- Other
- NFX-179